Fractyl Health Announced Single Administration Of Rejuva Reduced Fat Mass And Improved Glycemia In The Well-validated Diet-induced Obesity Mouse Model
Portfolio Pulse from Benzinga Newsdesk
Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data showing that a single administration of its Rejuva pancreatic gene therapy reduced fat mass and improved glycemia in a diet-induced obesity mouse model. The data was presented at the American Diabetes Association's 84th Scientific Sessions and highlighted as one of the President's Select Abstracts.
June 23, 2024 | 6:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fractyl Health's new preclinical data on Rejuva gene therapy shows promising results in reducing fat mass and improving glycemia, which could positively impact the company's stock price.
The positive preclinical results for Rejuva, presented at a major scientific conference, suggest potential future success in treating obesity and diabetes. This could lead to increased investor confidence and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100